Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites

Vivos Inc. (OTCQB: RDGL), a pioneering medical device company specializing in RadioGel® Radionuclide Therapy™ (PRnT™), is expanding its manufacturing capabilities with the planned establishment of two new production facilities in 2026. This initiative comes as part of the company's strategy to mitigate risks associated with relying on a single production site, as outlined in its corporate filings.

The new facilities will consist of a domestic site in Kennewick, Washington, and an international location, likely in India. The U.S. facility, located at the Applied Process Engineering Laboratory (APEL), is particularly significant as it will enable Vivos to become the manufacturer of record and focus on automated production. The site aims to produce Y-90 phosphate particles and combine them with sterile hydrogel for individual patient doses, enhancing production volumes and efficiency. The company has already ordered necessary manufacturing equipment and initiated installation, with licensing applications submitted.

Parallelly, Vivos is in discussions with experienced radiopharmaceutical contract manufacturers in India to expedite the establishment of its international production facility, which is expected to be operational by the end of 2026. This international presence is anticipated to streamline logistics, reduce shipping costs, and enhance access to global markets, thereby supporting the worldwide growth of its products, including RadioGel® for human oncology and IsoPet® for veterinary applications.

Through these strategic expansions, Vivos aims to solidify its position in the market and innovate in the development of precision radiotherapy solutions. Investors and stakeholders are encouraged to monitor Vivos' progress and forthcoming advancements as they unfold.

Vivos Inc. (OTCQB: RDGL) is strategically positioning itself for growth with the planned establishment of new production facilities in the U.S. and internationally. This diversification of manufacturing capabilities, particularly the transition from reliance on a single production site, addresses critical risk factors that have historically hindered the company’s operational stability.

The company's decision to set up a facility in Kennewick, Washington, at the Applied Process Engineering Laboratory (APEL), is a significant milestone. This site will not only serve as a manufacturing hub for its innovative RadioGel® Radionuclide Therapy™ but also implies a commitment to automation and operational efficiency. By having one production site domestically and exploring international options, Vivos is likely to enhance production capacity and streamline supplies, ultimately supporting its ambition to become a leading player in the oncology therapy market.

Moreover, Vivos's engagement with experienced radiopharmaceutical manufacturers in India for an international production facility could potentially reduce shipping costs and logistics complexities. Such a move would enhance its global reach and make its therapies, including RadioGel® and IsoPet®, more accessible to international markets. As Vivos Inc. progresses through 2026, investors should look for key indicators including the successful installation of manufacturing equipment at the APEL, operation commencement timelines for both U.S. and international sites, and updates on licensing applications.

However, prospective investors should remain cautious. The forward-looking statements in Vivos’s announcements highlight inherent risks in execution, regulatory approvals, and market acceptance of its products. Therefore, while the current expansion plans show promise, diligent monitoring of progress and market conditions is essential for stakeholders considering investment in Vivos Inc. as it embarks on this critical growth phase.